Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
July 2014

Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.

A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.

Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.

In Brief
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response

Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.

In Brief

July 2014

n May, the US FDA issued a warning that the sleep aid eszopiclone (Lunesta and others) can cause next-day impairment and lowered the recommended starting dose from 3 mg at bedtime to 1 mg (US Food and Drug Administration. Safety Announcement. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397277.pdf.…

To view the rest of this article, please: